FinnCap reiterated their corporate rating on shares of Cello Health (LON:CLL) in a report issued on Thursday morning, ThisIsMoney.Co.Uk reports.

Separately, Liberum Capital reaffirmed a hold rating on shares of Cello Health in a research report on Wednesday.

LON CLL traded up GBX 2 ($0.03) during trading hours on Thursday, hitting GBX 106.50 ($1.40). 48,219 shares of the company traded hands, compared to its average volume of 46,452. The business’s 50-day moving average is GBX 134.14 and its 200-day moving average is GBX 131.52. Cello Health has a twelve month low of GBX 111 ($1.46) and a twelve month high of GBX 150 ($1.97). The company has a debt-to-equity ratio of 4.70, a quick ratio of 1.23 and a current ratio of 1.28. The stock has a market capitalization of $111.11 million and a price-to-earnings ratio of 17.46.

The firm also recently disclosed a dividend, which will be paid on Friday, May 22nd. Stockholders of record on Thursday, April 23rd will be given a GBX 2.95 ($0.04) dividend. This represents a dividend yield of 2.85%. This is a boost from Cello Health’s previous dividend of $1.15. The ex-dividend date of this dividend is Thursday, April 23rd. Cello Health’s dividend payout ratio (DPR) is presently 0.66%.

Cello Health Company Profile

Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.

Further Reading: Cash Asset Ratio

Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with's FREE daily email newsletter.